FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597686565> ?p ?o ?g. }

• W2597686565 abstract "Osteosarcoma is the most common malignant bone tumour. Due to the high metastasis rate and drug resistance of this disease, multi-drug regimens are necessary to control tumour cells at various stages of the cell cycle, eliminate local or distant micrometastases, and reduce the emergence of drug-resistant cells. Many adjuvant chemotherapy protocols have shown different efficacies and controversial results. Therefore, we classified the types of drugs used for adjuvant chemotherapy and evaluated the differences between single- and multi-drug chemotherapy regimens using network meta-analysis.We searched electronic databases, including PubMed (MEDLINE), EmBase, and the Cochrane Library, through November 2016 using the keywords osteosarcoma, osteogenic sarcoma, chemotherapy, and random* without language restrictions. The major outcome in the present analysis was progression-free survival (PFS), and the secondary outcome was overall survival (OS). We used a random effect network meta-analysis for mixed multiple treatment comparisons.We included 23 articles assessing a total of 5742 patients in the present systematic review. The analysis of PFS indicated that the T12 protocol (including adriamycin, bleomycin, cyclophosphamide, dactinomycin, methotrexate, cisplatin) plays a more critical role in osteosarcoma treatment (surface under the cumulative ranking (SUCRA) probability 76.9%), with a better effect on prolonging the PFS of patients when combined with ifosfamide (94.1%) or vincristine (81.9%). For the analysis of OS, we separated the regimens to two groups, reflecting the disconnection. The T12 protocol plus vincristine (94.7%) or the removal of cisplatinum (89.4%) is most likely the best regimen.We concluded that multi-drug regimens have a better effect on prolonging the PFS and OS of osteosarcoma patients, and the T12 protocol has a better effect on prolonging the PFS of osteosarcoma patients, particularly in combination with ifosfamide or vincristine. The OS analysis showed that the T12 protocol plus vincristine or the T12 protocol with the removal of cisplatinum might be a better regimen for improving the OS of patients. However, well-designed randomized controlled trials of chemotherapeutic protocols are still necessary." @default.
• W2597686565 created "2017-04-07" @default.
• W2597686565 creator A5021379796 @default.
• W2597686565 creator A5042065068 @default.
• W2597686565 creator A5061830034 @default.
• W2597686565 creator A5065258787 @default.
• W2597686565 creator A5070461643 @default.
• W2597686565 creator A5086647275 @default.
• W2597686565 date "2017-03-29" @default.
• W2597686565 modified "2023-10-18" @default.
• W2597686565 title "Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials" @default.
• W2597686565 cites W106943784 @default.
• W2597686565 cites W1841030713 @default.
• W2597686565 cites W1902222293 @default.
• W2597686565 cites W1944507750 @default.
• W2597686565 cites W1946181835 @default.
• W2597686565 cites W1960987851 @default.
• W2597686565 cites W1979187129 @default.
• W2597686565 cites W1983587258 @default.
• W2597686565 cites W1989487705 @default.
• W2597686565 cites W2010423961 @default.
• W2597686565 cites W2017454339 @default.
• W2597686565 cites W2017476000 @default.
• W2597686565 cites W2030836189 @default.
• W2597686565 cites W2037593179 @default.
• W2597686565 cites W2058138047 @default.
• W2597686565 cites W2058182935 @default.
• W2597686565 cites W2067694228 @default.
• W2597686565 cites W2070248730 @default.
• W2597686565 cites W2085716946 @default.
• W2597686565 cites W2091213994 @default.
• W2597686565 cites W2095599995 @default.
• W2597686565 cites W2095939529 @default.
• W2597686565 cites W2098923148 @default.
• W2597686565 cites W2100877728 @default.
• W2597686565 cites W2103017208 @default.
• W2597686565 cites W2103405666 @default.
• W2597686565 cites W2104608305 @default.
• W2597686565 cites W2104953667 @default.
• W2597686565 cites W2108509276 @default.
• W2597686565 cites W2113319228 @default.
• W2597686565 cites W2122848022 @default.
• W2597686565 cites W2129263123 @default.
• W2597686565 cites W2131112855 @default.
• W2597686565 cites W2156098321 @default.
• W2597686565 cites W2163165105 @default.
• W2597686565 cites W2164650822 @default.
• W2597686565 cites W2165678358 @default.
• W2597686565 cites W2171049508 @default.
• W2597686565 cites W2182768463 @default.
• W2597686565 cites W2213721523 @default.
• W2597686565 cites W2342753810 @default.
• W2597686565 cites W2373184113 @default.
• W2597686565 cites W2396199921 @default.
• W2597686565 cites W2401706436 @default.
• W2597686565 cites W2416986342 @default.
• W2597686565 cites W2431282426 @default.
• W2597686565 cites W246286872 @default.
• W2597686565 cites W2513951655 @default.
• W2597686565 cites W2588681363 @default.
• W2597686565 cites W4210860827 @default.
• W2597686565 cites W4294215472 @default.
• W2597686565 cites W4298270614 @default.
• W2597686565 doi "https://doi.org/10.1186/s13018-017-0544-9" @default.
• W2597686565 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5372345" @default.
• W2597686565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28356114" @default.
• W2597686565 hasPublicationYear "2017" @default.
• W2597686565 type Work @default.
• W2597686565 sameAs 2597686565 @default.
• W2597686565 citedByCount "17" @default.
• W2597686565 countsByYear W25976865652017 @default.
• W2597686565 countsByYear W25976865652018 @default.
• W2597686565 countsByYear W25976865652020 @default.
• W2597686565 countsByYear W25976865652021 @default.
• W2597686565 countsByYear W25976865652022 @default.
• W2597686565 countsByYear W25976865652023 @default.
• W2597686565 crossrefType "journal-article" @default.
• W2597686565 hasAuthorship W2597686565A5021379796 @default.
• W2597686565 hasAuthorship W2597686565A5042065068 @default.
• W2597686565 hasAuthorship W2597686565A5061830034 @default.
• W2597686565 hasAuthorship W2597686565A5065258787 @default.
• W2597686565 hasAuthorship W2597686565A5070461643 @default.
• W2597686565 hasAuthorship W2597686565A5086647275 @default.
• W2597686565 hasBestOaLocation W25976865651 @default.
• W2597686565 hasConcept C126322002 @default.
• W2597686565 hasConcept C141071460 @default.
• W2597686565 hasConcept C142724271 @default.
• W2597686565 hasConcept C143998085 @default.
• W2597686565 hasConcept C2776478404 @default.
• W2597686565 hasConcept C2776694085 @default.
• W2597686565 hasConcept C2776755627 @default.
• W2597686565 hasConcept C2777506904 @default.
• W2597686565 hasConcept C2777760704 @default.
• W2597686565 hasConcept C2778239845 @default.
• W2597686565 hasConcept C2779429289 @default.
• W2597686565 hasConcept C2781413609 @default.
• W2597686565 hasConcept C71924100 @default.
• W2597686565 hasConcept C95190672 @default.
• W2597686565 hasConceptScore W2597686565C126322002 @default.
• W2597686565 hasConceptScore W2597686565C141071460 @default.

• next